Tagged with ANAFAM

Mexico Whenever the international investor community contemplates doing business in Mexico’s life science sector, the primary appeal usually derives from the sheer size of the marketplace and its underlying growth potential associated with trends in the country’s population demographics. Much attention is thus given over to devising strategies to win public…

Mexico Mexico has become a major player in global manufacturing, attracting companies looking to bring supply chains closer to North American markets, but home-grown pharma companies are also capitalizing on the country’s manufacturing muscle, increasing capabilities while betting on quality and aiming for international markets. Recent PharmaBoardroom interviewees share their insights.…

Mexico The Mexican National Association of Drug Manufacturers (ANAFAM) aims to support its members through advocacy, regulatory support, and professional development. The association’s president, Dr Miguel Lombera, emphasises the importance of ensuring universal healthcare coverage and equal access to primary healthcare and vaccination for all Mexicans; how frequent changes in Mexico’s…

Mexico María del Socorro España Lomelí, the executive director of Mexico’s National Association of Manufacturers of Medicines (ANAFAM), speaks to PharmaBoardroom about ANAFAM’s evolving relationship with the Mexican government and the changes in the country’s procurement law, which gave rise to widespread procurement issues. She also discusses ANAFAM member companies’ internationalisation…

Mexico CP Maria del Socorro España Lomeli, executive director of the Mexican generics industry association ANAFAM, discusses the challenges with regard to the ‘new rules of the game’ in Mexico’s healthcare sector since 2018, the willingness of the Mexican pharmaceutical industry to be a trusted ally to the public healthcare system,…

Pharma Socorro España Lomelí, executive director of Mexico’s National Association of Drug Manufacturers (ANAFAM), details her strategic priorities with regards to the promotion of the industry’s export strategy, the implementation of world-class manufacturing norms, the development of biosimilars and API manufacturing, as well as recognizing the pharmaceutical sector as a strategic…

ANAFAM This is your 3rd interview with Focus Reports. What would you say has been the biggest change that has shaped the pharmaceutical industry since we last interviewed you in 2008? The main change in the last 4 years has been the close relationship that we’ve established with the authorities. Before…